This study is investigating Blinatumomab in combination with chemotherapy in patients with newly diagnosed standard risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the treatment of patients with localized B-Lymphoblastic Lymphoma (B-LLy).

Blinatumomab is an investigational drug which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

The purpose of this study is to test the good and bad effects of a drug called M3814 in combination with the drug avelumab and radiation therapy for advanced/metastatic solid tumors and hepatobiliary malignancies.

The purpose of this study is to determine if adding ablative local therapy (ALT) to the usual approach of systemic therapy for treatment of metastatic colorectal cancer can lengthen survival and if this approach is better or worse than the usual approach. ALT may be performed by surgery, radiation therapy, heat with microwave ablation, or other methods. This study will use radiation therapy and potentially surgery and/or heat. 

This clinical trial is for adults who have metastatic breast cancer with a BRCA 1 or BRCA 2 mutation of the tumor detectable by blood or tumor tissue.
   

This clinical trial is for men and women who have a solid tumor cancer (not a blood cancer) that has worsened and has not responded to at least one prior cancer treatment. Participants’ tumor DNA must also have an error in one of the genes associated with the homologous recombination (HR) pathway including but not limited to BRCA1 or 2 (Breast Cancer 1 or 2).
   

This clinical trial is for men and women who have been diagnosed with colorectal cancer that has spread to their liver and are eligible for standard of care surgery to remove tumors in their liver.
   

This clinical trial is for men and women who have been diagnosed with an advanced type of multiple myeloma (MM) and their cancer has returned after taking 3 or more other cancer medications (this is called relapsing) or those medications did not work (this is called refractory). Other study sites are also enrolling patients who have non-Hodgkin’s lymphoma (NHL), but Weill Cornell Medicine is only enrolling participants who have multiple myeloma (MM).
   

The goal of this study is to better understand the biology underlying plasma cell disorders.

To accomplish this goal, we have created a database-biorepository which is being used by investigators at Weill Cornell Medicine and their collaborators. By studying the clinical course of patients with plasma cell disorders, and by performing basic laboratory studies using their tissue, we hope to improve patient care.

The purpose of this study is to better understand how well the medication REBYOTA is working to prevent recurrence of CDI (Clostridioides Difficile Infection) among adults following antibiotic treatment. The study also aims to understand patient-reported outcomes and health care utilization (e.g., doctors’ visits, and hospitalizations) after receiving REBYOTA. 

REBYOTA prevents recurrence of CDI among adults following antibiotic treatment and this drug is approved by the U.S. Food and Drug Administration (FDA).

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma.